All authors critically revised the manuscript for intellectual content. one oxPTM-INS were present in 91.3% of progr-T1D children. oxPTM-INS-Ab co-existed with GADA, IA-2A, IAA or ZnT8A in 65.2%, 56.5%, 38.9% and 33.3% progr-T1D children, respectively. In addition, oxPTM-INS-Ab were present in 17.4%, 26.1%, 38.9% and 41.6% of progr-T1D children who were negative for GADA, IA-2A, IAA and ZnT8A, respectively. ?OH-INS-Ab were more common in progr-T1D children than in NP-AAB+ children (82.6% vs 19%; and and these were categorised as susceptibility-associated ISRIB (S), neutral (N) and protective (P), according to Hermann et al [24]. Susceptibility-associated haplotypes included (((((((((%) The three groups were comparable in terms of sex, although age was slightly higher in the NP-AAB+ group than in the progr-T1D group ((%) HLA haplotypes were available in 43 children and were categorized into susceptibility-associated (S), neutral (N) and protective (P) groups according to Hermann et al. [24]. Susceptibility-associated haplotypes included (((((((([4]. In this regard, the extracellular matrix surrounding beta cells [29], or other tissues attacked by Rabbit Polyclonal to B3GALTL autoimmune response in type 1 diabetes (thyroid, gut, joints, etc) [30], may become additional potential targets of oxPTM [4, 31]. Often such PTM forms induce a more pronounced immune reactivity than the native antigen. Our results may also have implications for disease prediction and staging. Consistent with previous findings [15, 32], we found low predictive accuracy of GADA and IAA when analysed as a single test, while IA-2A showed a highly specific association with type 1 diabetes progression [15]. A main obtaining of our study is the predictive accuracy of oxPTM-INS-Ab. Of notice, oxPTM-INS-Ab recognized individuals with preclinical disease otherwise classified as antibody-negative or single-positive. As highlighted by a recent statement by the JDRF, Endocrine Society and ADA, islet autoimmunity (as defined by the presence of two or more islet autoantibodies) represents the earliest stage of type 1 diabetes and identifies a target populace for prevention trials and future preventive strategies [33]. If confirmed in ISRIB larger studies, oxPTM-INS-Ab may be adopted as an additional biomarker to further redefine disease taxonomy, allowing better prediction and therefore better stratification into eligibility trials. In conclusion, we showed that immune reactivity to oxPTM-INS is present before clinical onset of type 1 diabetes and that measurement of oxPTM-INS-Ab may identify children likely to progress to type 1 diabetes. This is the first evidence suggesting that oxPTM of a beta cell autoantigen precedes diabetes onset in humans and that auto-reactivity to oxPTM may act as a predictive biomarker of the disease. Additional studies with larger cohorts are required to confirm the predictive potential of oxPTM-INS-Ab in type 1 diabetes. Abbreviations ABISAll Babies in Southeast SwedenGADAGAD autoantibodiesGLY-INSGlycated insulinHELHen egg lysozymeHOCl-INSHOCl-modified insulinIA-2ATyrosine phosphatase autoantibodiesIAAInsulin autoantibodies?OH-INS ?OH-modified insulinNT-INSNative insulinoxPTMOxidative PTMoxPTM-HELOxidative post-translationally altered HELoxPTM-INSOxidative post-translationally altered insulinoxPTM-INS-AbAntibodies to oxPTM-INSprogr-T1DProgressing to type 1 diabetes;NP-AAB+Autoantibody-positive, non-progressing to type 1 diabetesNP-AAB?Autoantibody-negative, non-progressing to type 1 diabetesPTMPost-translational modificationRBARadiobinding assayZnT8AZinc transporter 8 autoantibodies Notes Data availability The data are available on request from your authors. Funding This study was supported by the EFSD/JDRF/Lilly European Programme in Type 1 Diabetes Research (3-PAR-2016-277-A-N) and by the JDRF innovative grant (INO-2015-78-S-B). ABIS and the autoantibody determinations were supported by the Swedish Research Council (K2005-72X-11242-11A and K2008-69X-20826-01-4), the Swedish Child Diabetes Foundation (Barndiabetesfonden), JDRF Wallenberg Foundation (K 98-99D-12813-01A), Medical Research Council of Southeast Sweden (FORSS) and the Swedish Council for Working Life and Social Research (FAS2004C1775). Duality of interest The authors declare that there is no duality of interest associated ISRIB with this manuscript. Contribution statement RS, PP, JL and AN conceived the study. CV contributed to acquisition and analysis of data. NN contributed to data acquisition. RS analysed the data and had written the 1st draft. All authors revised the manuscript for intellectual content material critically. All authors have observed and approved the ultimate draft. RS may be the guarantor of the ongoing function and, as such, got full usage of all of the data in the analysis and requires responsibility for the integrity of the info as well as the precision of the info evaluation. Footnotes Paolo Pozzilli, Johnny Ahuva and Ludvigsson Nissim talk about older authorship. Contributor Info Paolo Pozzilli, Email: ti.supmacinu@illizzop.p. Ahuva.